このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
CLVS.Q 株式概要
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
Clovis Oncology, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.015 |
| 52週高値 | US$2.87 |
| 52週安値 | US$0.01 |
| ベータ | 0.66 |
| 11ヶ月の変化 | -40.00% |
| 3ヶ月変化 | -28.57% |
| 1年変化 | -99.39% |
| 33年間の変化 | -99.77% |
| 5年間の変化 | -99.97% |
| IPOからの変化 | -99.88% |
最新ニュース
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05株主還元
| CLVS.Q | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 18.1% | -1.6% | -0.06% |
| 1Y | -99.4% | 10.4% | 20.5% |
業界別リターン: CLVS.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
リターン対市場: CLVS.Q underperformed the US Market which returned 12.6% over the past year.
価格変動
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: CLVS.Q's share price has been volatile over the past 3 months.
時間の経過による変動: CLVS.Q's weekly volatility has increased from 39% to 61% over the past year.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc. 基礎のまとめ
| CLVS.Q 基礎統計学 | |
|---|---|
| 時価総額 | US$2.18m |
| 収益（TTM） | -US$251.91m |
| 売上高(TTM) | US$133.02m |
0.0x
P/Sレシオ0.0x
PER（株価収益率CLVS.Q は割高か？
公正価値と評価分析を参照収益と収入
| CLVS.Q 損益計算書（TTM） | |
|---|---|
| 収益 | US$133.02m |
| 売上原価 | US$31.59m |
| 売上総利益 | US$101.43m |
| その他の費用 | US$353.33m |
| 収益 | -US$251.91m |
直近の収益報告
Sep 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.73 |
| グロス・マージン | 76.25% |
| 純利益率 | -189.37% |
| 有利子負債／自己資本比率 | -158.0% |
CLVS.Q の長期的なパフォーマンスは？
過去の実績と比較を見る